NMR-Based Fragment Screening For Drug Discovery

Seminar Overview

Fragment-based screening (FBS) has emerged over the last 15 years as a widely used alternative to high-throughput screening (HTS) for the identification of lead compounds in drug discovery. It has helped to address many of the limitations of HTS, requiring significantly fewer compounds to be screened and synthesized, and results in a higher hit rate than traditional screening methods.

There are a number of biophysical methods used for fragment screening from which NMR is the most popular and reliable techniques and is used in more than 50% of fragment screening campaigns. NMR is ideally suited for detecting low affinity ligands in primary screens. In addition, screening by NMR allows quality control of the screening library which makes NMR superior to other methods. However, a drawback is the number of spectra generated, sometimes in the 100s or 1000s, which must be analyzed manually in parallel by a trained operator – a time-consuming, labor-intensive activity that creates a substantial bottleneck in the process.

In this webinar, Stefan Jehle, Ph.D. and Pavel Kessler, Ph.D. from Bruker BioSpin will outline how Bruker’s TopSpin software, together with a newly launched FBS tool, can help overcome this stumbling block by facilitating the workflow, improving efficiency and minimizing human error.


Stefan Jehle, Ph.D. (Biography), Product Manager - Bruker Solutions for Fragment Based Drug Discovery - Fällanden, Switzerland

Pavel Kessler, Ph.D. (Biography), Group Leader User Experience - Bruker MRS Application Development - Rheinstetten, Germany

What you will discover

This webinar will explain how Bruker’s TopSpin software can simplify FBS by NMR.

Key topics include:

  • Introduction to the TopSpin FBS tool
  • Software customization options
  • Automation solutions in NMR
  • Detection hardware and cryoprobes
  • Druggability assessment and ID of aggregating molecules

Stefan Jehle, Ph.D. is a product manager at Bruker for solutions in fragment based screening using NMR who has extensive experience in solution and solid-state NMR spectroscopy, and has previously carried out research into FBS lead discovery during his time at Boston University.

Presenting this webinar alongside Dr. Jehle is Pavel Kessler, Ph.D. who works on user experience at Bruker. Dr. Kessler has over three decades of experience in software development for NMR and is responsible for the development of Bruker’s FBS tool for TopSpin.

During this webinar, the pair will introduce you to Bruker’s newly launched FBS tool that works within the TopSpin software. They will explain how it helps to greatly accelerate data analysis during NMR-based FBS by incorporating all screening data into one place and automating many of the processes that are usually done manually.

When the tool is launched, all relevant data, experiment types, compound IDs, reference spectra and other information is automatically collected and stored in a project file. During analysis, the software also automatically saves each action, including any hits, ensuring accurate records and freeing up operators to focus on applying their chemical knowledge.

They will describe what makes the software so user-friendly, and easy to incorporate into existing workflows, as well as creating scope for people without an expert knowledge of data analysis to conduct this kind of research.

Who should attend

This webinar will be of interest to anyone working in drug discovery, whether it be in the pharmaceutical industry, contract research organizations or academia, including those with no prior experience in FBS.

Other Webinars from Bruker BioSpin - NMR, EPR and Imaging

Tell Us What You Think

Do you have a review, update or anything you would like to add to this content?

Leave your feedback
Your comment type

Materials Webinars by Subject Matter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.